Keyphrases
Human Papillomavirus Vaccine
76%
HPV16
71%
High-risk Human Papillomavirus (HR-HPV)
69%
Vaccination
48%
Cluster Randomized Trial
29%
Gender Neutral
25%
Finland
25%
Population-based
22%
Vaccine Effectiveness
20%
Unvaccinated
19%
HPV6
19%
Head-to-head Comparison
19%
Vaccination Strategy
18%
Community-randomized Trials
18%
Herd Effect
17%
Cervical Cancer Screening
16%
Human Papillomavirus Types
15%
Birth Cohort
15%
Bivalent Vaccine
13%
Gender-neutral Vaccination
13%
Revaccination
12%
Seroprevalence
12%
Vaccine Response
12%
Registry-based
11%
Phase II Trial
11%
Hepatitis B Vaccine
11%
Vaccination Program
11%
Oncogenic Human Papillomavirus
11%
Cervical Cancer
10%
HPV18
9%
Quadrivalent Vaccine
9%
Gender-based
9%
Pregnant Women
9%
Preterm Birth Rate
9%
Vaccine Registry
9%
Oral Contraceptives
9%
Nonavalent
9%
Cross-sectional Cohort
9%
Squamous Intraepithelial Lesion
9%
Cervical High-grade Squamous Intraepithelial Lesions
9%
Methylation Markers
9%
Adult Women
9%
European Countries
9%
Vaccine Uptake
9%
Randomized Clinical Trial
9%
High-grade Squamous Intraepithelial Lesion
9%
Quadrivalent Human Papillomavirus Vaccine
9%
Diversity Profiles
9%
Ecological Diversity
9%
C.trachomatis
9%
Medicine and Dentistry
Wart Virus
100%
Human Papillomavirus Type 16
59%
Wart Virus Vaccine
50%
Cluster Randomized Trial
29%
Arm
26%
Human Papillomavirus Type 6
22%
Vaccine Efficacy
20%
Adolescence
17%
Herd
16%
Cervical Cancer Screening
15%
Cervical Cancer
13%
Seroprevalence
11%
Antibody Response
10%
Premature Labor
9%
Neutralizing Antibody
9%
Birth Rate
9%
Oral Contraceptive
9%
Randomized Clinical Trial
9%
Methylation
9%
Cohort Analysis
9%
Chlamydia Infection
9%
Adenocarcinoma in Situ
9%
Cervical Intraepithelial Neoplasia
9%
Cancer
9%
Vaccination Coverage
9%
Human Papillomavirus Type 18
9%
Cancer Registry
7%
AS04
7%
Human Papillomavirus Type 31
6%
Oral Contraceptive Use
6%
Hepatitis B Vaccine
5%
Immunology and Microbiology
Wart Virus
63%
Human Papillomavirus Type 16
38%
Cervarix
21%
Arm
19%
Human Papillomavirus Type 6
13%
Seroprevalence
11%
Antibody Response
10%
Neutralizing Antibody
9%
Methylation
9%
Vaccination
9%
Birth Rate
9%
Human Papillomavirus Type 31
6%
Cancer Screening
6%
Herd
5%